Current Report Filing (8-k)
20 10월 2017 - 5:40AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 4, 2017
|
PROTO SCRIPT PHARMACEUTICAL CORP.
|
|
(Exact name of registrant as specified in charter)
|
|
Nevada
|
|
333-175146
|
|
99-0363803
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
9830 6th Street, Suite 103
Rancho Cucamonga, California
|
|
91730
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(855) 476-7679
Registrant’s telephone number
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.
On October 4, 2017, Proto Script Pharmaceutical Corp. (the “Company”) was notified from its registered public accounting firm (the “Auditor”) that the Auditor had provided the Company with consent to file the Company’s Form 10-K for the fiscal year ended December 31, 2016 which the Company previously filed with the Commission on September 20, 2017, prior to receiving final consent to file by the Auditor’s EQR Partner.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROTO SCRIPT PHARMACEUTICAL CORP.
|
|
|
|
|
|
|
|
Date: October 19, 2017
|
By:
|
/s/ Michelle Rico
|
|
|
|
|
Michelle Rico, President
|
|
Proto Script Pharmaceuti... (CE) (USOTC:PSCR)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Proto Script Pharmaceuti... (CE) (USOTC:PSCR)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
Proto Script Pharmaceutical Corporation (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Proto Script Pharmaceutical Corp News Articles
